ORIC-101 is a highly potent and selective glucocorticoid receptor antagonist, with an EC 50 of 5.6 nM. Anti-cancer activity. In Vitro ORIC-101 shows markedly reduced androgen receptor agonism (EC 50 , 2500 nM) and CYP2C8 and CYP2C9 inhibition profiles (IC 50 , >10 μM). ORIC-101 (1-1000 nM) dose-dependently reduces the expression of n GR-mediated target gene (FKBP5 and GILZ), with IC 50 s of 17.2 and 21.2 nM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo ORIC-101 (75 mg/kg, P.O. twice a day for 16-22 days) enhances the anti-tumor activity in combination with gemcitabine and carboplatin in OVCAR5 xenograft tumor in cortisol-treated mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: OVCAR5 xenograft tumor in cortisol-treated mice Dosage: 75 mg/kg with 100 mg/kg gemcitabine and 60 mg/kg carboplatin Administration: P.O. twice a day for 16-22 days Result: Significantly reduced tumor volume in combination with chemotherapeutic agents. Form:Solid IC50& Target:EC50: 5.6 nM (Glucocorticoid receptor)
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
ORIC-101
CAS number：2222344-98-9 molecular formula：C34H47NO2
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 2222344-98-9 | molecular formula | C34H47NO2 |
| molecular weight | 501.74 g/mol | Exact mass | ≥99% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
